Form 4: American Oncology Network Director Acquires 5,000 Shares of Class A Common Stock

Bradley M. Fluegel, a director of American Oncology Network, Inc., acquired 5,000 shares of Class A Common Stock on July 16, 2024, as part of his compensation for serving on the Board of Directors.

Summary

• On July 16, 2024, Bradley M. Fluegel, a director of American Oncology Network, Inc. (AONC), acquired 5,000 shares of Class A Common Stock.
• The acquisition was reported on a Form 4 filing with the SEC.
• These shares were granted as compensation for his service as an independent director on the American Oncology Network, Inc. Board of Directors.
• Of the 5,000 shares, 3,250 will vest on a time-based schedule over four years, and 1,750 will vest based on a performance-based schedule.
• Following the transaction, Fluegel directly owns 44,981 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The document reports a standard director compensation in the form of stock, which is generally viewed as a positive sign of alignment with shareholder interests. There are no indications of negative news or concerns.

Positives

• The acquisition of shares by a director demonstrates their alignment with the company's success.
• The vesting schedule (both time-based and performance-based) incentivizes long-term commitment and performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company insiders.

Comparison to Industry Standards

• Director compensation packages often include stock grants to align their interests with shareholders, a common practice among publicly listed companies.
• Vesting schedules, like the four-year time-based and performance-based vesting, are standard in the industry to ensure long-term commitment.
• Similar stock grants are seen at companies like McKesson and UnitedHealth Group for their board members.

Stakeholder Impact

• Shareholders may view the director's stock acquisition as a positive sign, indicating confidence in the company's future.
• The vesting schedule incentivizes the director to contribute to the company's long-term success.

Key Dates

Keywords

Form 4, AONC, American Oncology Network, Director, Bradley Fluegel, Stock Acquisition, Class A Common Stock, Beneficial Ownership, SEC Filing, Vesting Schedule